KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Capital Expenditures (2016 - 2025)

Rigel Pharmaceuticals has reported Capital Expenditures over the past 15 years, most recently at -$12000.0 for Q4 2025.

  • Quarterly results put Capital Expenditures at -$12000.0 for Q4 2025, down 146.15% from a year ago — trailing twelve months through Dec 2025 was $276000.0 (up 9.52% YoY), and the annual figure for FY2024 was $36000.0, changed.
  • Capital Expenditures for Q4 2025 was -$12000.0 at Rigel Pharmaceuticals, down from $26000.0 in the prior quarter.
  • Over the last five years, Capital Expenditures for RIGL hit a ceiling of $407000.0 in Q2 2021 and a floor of -$36000.0 in Q2 2022.
  • Median Capital Expenditures over the past 4 years was $72000.0 (2021), compared with a mean of $109100.0.
  • Biggest five-year swings in Capital Expenditures: surged 1025.0% in 2021 and later plummeted 146.15% in 2025.
  • Rigel Pharmaceuticals' Capital Expenditures stood at -$21000.0 in 2021, then soared by 447.62% to $73000.0 in 2022, then plummeted by 64.38% to $26000.0 in 2024, then plummeted by 146.15% to -$12000.0 in 2025.
  • The last three reported values for Capital Expenditures were -$12000.0 (Q4 2025), $26000.0 (Q4 2024), and $73000.0 (Q4 2022) per Business Quant data.